

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Date: 30/07/2021

Dear Sir / Madam,

SYMBOL: AJOONI

Sub: Reply to Observations for the Results submitted for the half year ended September 30, 2020.

Dear Sir,


With reference to the observations regarding deficiency and non-submission, we would like to clarify that we have submitted the replies for the same regarding the query raised on Financial Results and submission of Cash Flow.

We hereby state that due to Technical difficulty in the website of NSE, we were not able to upload the Financial Results at "Quick Results" tab and hence uploaded/submitted the same at "Financial Results Updates" tab.

Further, we also tried to contact the helpdesk of NSE many times to avail technical assistance but could not get any assistance/ could not connect, regarding the reply for clarification sought.

Therefore, we hereby request you to kindly consider take the same on record.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited
Swati Vijan
Company Secretary



To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Date: 19/04/2021

Dear Sir / Madam,

SYMBOL: AJOONI

Sub: Reply to Observations to your e-mail dated 17th April 2021

Dear Sir,

With reference to your e-mail dated **17th April 2021** regarding deficiency and non-submission, we would like to clarify that we have submitted the reply thrice, regarding the same queries raised on Financial Results and submission of Cash Flow.

Further, we would also like to submit that due to Technical difficulty in the website of NSE, we were not able to upload the Financial Results at "Quick Results" tab and hence uploaded/submitted the same at "Financial Results Updates" tab.

We also tried to contact the helpdesk of NSE many times to avail technical assistance but could not get any assistance/ could not connect, regarding the reply for clarification sought. This is for your necessary information.

Therefore, we hereby request you to kindly take the same on record.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited

Swati Vajan
Company Secretary





AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)
Phone : 0172 - 5020758 - 69 Website : www.ajoonibiotech.com
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

To,
EMERGE PLATFORM OF NSE
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Date: 10/02/2021

Dear Sir / Madam,

SYMBOL: AJOONI

Sub: Reply to Observations to your e-mail dated 09th February 2021


Dear Sir,

With reference to your e-mail dated 9th Feb, 2021 regarding deficiency and non-submission, we would like to clarify that we have submitted the reply twice, regarding the same queries raised on Financial Results and submission of Cash Flow.

Further, we would also like to submit that due to Technical difficulty in the website of NSE, we were not able to upload the Financial Results at "Quick Results" tab and hence uploaded/submitted the same at "Financial Results Updates" tab.

We also tried to contact the helpdesk of NSE many times to avail technical assistance but could not get any assistance/ could not connect, regarding the reply for clarification sought. This is for your necessary information.

Therefore, we hereby request you to kindly take the same on record.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited

Swati Vijan
Company Secretary



AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)
Phone : 0172 - 5020758 - 69 Website : www.ajoonibiotech.com
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

To,
EMERGE PLATFORM OF NSE
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Date: 06/01/2021

Dear Sir / Madam,

SYMBOL: AJOONI

Sub: Reply to Observations to your e-mail dated 05th January 2021

Dear Sir,

With reference to your e-mail dated : 05th Jan, 2021 regarding deficiency and non-submission, we would like to clarify as follows:

a) We have submitted the Financial Results within 30 minutes from the conclusion of Board Meeting as our Board Meeting concluded at 4:30 pm and we have uploaded the Financial Results at 04:46:41 pm. NSE Acknowledgement for the same is attached for your kind reference.

Further, we would also like to submit that due to Technical difficulty in the website of NSE, we were not able to upload the Financial Results at "Quick Results" tab and hence uploaded/submitted the same at "Financial Results Updates" tab. We also tried to contact the helpdesk of NSE regarding this issue but didn't get any response and hence uploaded the Financial Results at "Financial Results Updates" tab. This is for your necessary information.

b) Further, we have submitted the Cash Flow Statement on 23rd November, 2020 on receipt of your e-mail dated: 20th November, 2020 and also attached the same along with this mail.

Therefore, we hereby request you to kindly take the same on record.


Thanking You,

Yours Truly,

For Ajooni Biotech Limited

Swati Vihar

Company Secretary





National Stock Exchange Of India Limited

Date of Download : 23-Nov-2020

FINANCIAL RESULTS ACK. / REG 33 ACK

Symbol:-	AJOONI
Name of the Company: -	Ajooni Biotech Limited
Submission Type:-	Quick Results
Quarter/Period Ended: -	30-Sep-2020
BM Submission:-	10-Nov-2020 14:30
Date and Time of Submission:-	10-Nov-2020 16:53

We hereby acknowledge receipt of Financial Results through NEAPS. The Financial Results will be disseminated on website as received and in no event will NSEIL be liable for any mistakes, errors or omissions in the Financial Results.



AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)
Phone : 0172 - 5020758 - 69 Website : www.ajoonibiotech.com
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

To,
EMERGE PLATFORM OF NSE
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Date: 23/11/2020

Dear Sir / Madam,

SYMBOL: AJOONI

Sub: Reply to Observations to your e-mail dated 20th November 2020


Dear Sir,

This is with reference to your e-mail dated 20th November 2020 regarding Half yearly Financial Results for 30th September 2020, kindly note that in this regard, we are enclosing herewith Cash Flow Statement with un-audited results for half year ended 30th September 2020.

Further, we would like to state that meeting started at 4.00 pm and concluded at 4.30 pm, in this regard, results in pdf format were submitted on time as per Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015 under the head Financial results Updates. Copy of acknowledgement attached.

You are requested to kindly take the same on record.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited


Swati Vihar
Company Secretary
(ACS: 39179)

AJOONI BIOTECH LIMITED
CIN : U85190PB2010PLCO40162

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30.09.2020 (RS. IN LAKHS)

PARTICULARS	Half Yearly			Yearly	
	30.09.2020 (Unaudited)	31.03.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)	31.03.2019 (Audited)
I Revenue From Operations	2194.20	2356.93	1646.33	4003.26	3971.81
II Other Income	0.73	-8.52	14.51	5.99	33.86
III TOTAL REVENUE (I + II)	2,194.93	2,348.41	1,660.84	4,009.25	4,005.67
IV EXPENSES:					
Cost of Material Consumed	1874.65	1866.01	1446.86	3493.59	3646.48
Purchase of Stock-In-Trade	0.00	0.00	0.00	0.00	0.00
Change In Inventories	-20.69	185.47	-6.27	-2.39	0.72
Finance Cost	20.80	19.29	13.50	32.79	10.71
Employee Benefit Expenses	62.48	45.54	66.26	111.80	72.13
Depreciation and amortization	21.30	17.56	31.63	49.19	43.82
Other Expenses	183.94	177.34	97.96	276.17	184.32
TOTAL EXPENSES	2,142.48	2,311.21	1,649.94	3,961.15	3,958.18
V PROFIT / (LOSS) FROM OPERATION BEFORE EXCEPTIONAL AND EXTRAORDINARY ITEMS AND TAX (III-IV)	52.45	37.20	10.90	48.10	47.49
VI Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII PROFIT / (LOSS) BEFORE EXTRAORDINARY ITEMS AND TAX (V-VI)	52.45	37.20	10.90	48.10	47.49
VIII Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX PROFIT / (LOSS) BEFORE TAX (VII-VIII)	52.45	37.20	10.90	48.10	47.49
X TAX EXPENSE:					
(1) Current Tax	13.60	14.00	2.83	16.83	11.75
(2) Deferred Tax	0.00	3.44	0.00	3.44	-5.35
(3) MAT Credit	0.00	0.00	0.00	0.00	0.00
XI NET PROFIT / (LOSS) FROM CONTINUING OPERATIONS (VII-VIII)	38.85	19.76	8.07	34.71	41.10
XII NET PROFIT / (LOSS) FROM DISCONTINUING OPERATIONS	0.00	0.00	0.00	0.00	0.00
XIII TAX EXPENSE OF DISCONTINUING OPERATIONS	0.00	0.00	0.00	0.00	0.00
XIV NET PROFIT / (LOSS) FROM DISCONTINUING OPERATIONS (after Tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV Profit/Loss for the period(XI+XIV)	38.85	19.76	8.07	34.71	41.10
XVI NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *	38.85	19.76	8.07	34.71	41.10
XVII Paid-up equity share capital (Face Value of the Share shall be indicated)	840.50	840.50	615.50	840.50	615.50
XVIII Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	840.50	840.50	615.50	840.50	615.50
XIX Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):					
(1) BASIC	0.46	0.24	0.13	0.41	0.67
(2) DILUTED	0.46	0.24	0.13	0.41	0.67
XX Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):					
(1) BASIC	0.46	0.24	0.13	0.41	0.67
(2) DILUTED	0.46	0.24	0.13	0.41	0.67

* Applicable in the case of consolidated results.

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th November 2020.

2. Segment Reporting is not applicable, since the company is involved in one segment only

For and on behalf of Board of Ajooni Biotech Limited

Place : Mohali
Date : 10/11/2020



Jasjot Singh
Director
DIN: 01937631


AJOONI BIOTECH LIMITED
CIN : U85190PB2010PLC040162

STATEMENT OF ASSETS AND LIABILITIES

UNDER REGULATION 33 OF THE SEBI(USTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS,
2015

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES (RS. IN LAKHS)

PARTICULARS	30.09.2020	30.09.2019	year ended 31.03.20
	unaudited	unaudited	Audited
<u>I EQUITY AND LIABILITIES</u>			
(1) <u>Shareholders' funds</u>			
(a) Equity Share Capital	840.50	615.50	840.50
(b) Reserves and surplus	787.45	622.03	748.60
(2) <u>Non-Current Liabilities</u>			
(a) Long Term Borrowings	224.93	430.15	133.07
(3) <u>Current Liabilities</u>			
(a) Short Term Borrowings	323.69	207.33	369.46
(b) Trade Payables	253.99	151.44	193.28
(c) Other Current Liabilities	23.25	87.79	4.46
(d) Short Term Provisions	30.43	0.62	17.38
TOTAL Rs.	2,484.24	2,114.86	2,306.75
<u>I. ASSETS</u>			
(1) <u>Non - Current Asset</u>			
(a) Property, Plant and Equipment			
(i) Tangible Assets	251.48	104.33	207.15
(b) Non-Current Investments	296.16	363.02	307.87
(c) Long Term Loans & Advances	36.02	111.72	
(d) Deferred Tax Asset	12.74	9.29	12.74
(e) Other Non Current Assets	21.10	42.21	28.14
(2) <u>Current Assets</u>			
(a) Inventories	349.26	506.00	328.57
(b) Trade Receivables	1,261.91	805.52	1,264.19
(c) Cash & Cash Equivalent	20.92	29.85	12.39
(d) Short Term Loans and advances	213.61	142.91	124.67
(e) Other Current Asset	21.04	-	21.04
TOTAL Rs.	2,484.24	2,114.85	2,306.75





Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Independent Auditor's Limited Review Report on the Half Yearly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,


**The Board of Directors,
Ajooni Biotech Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Ajooni Biotech Limited** ("the Company") for the Half Year ended September 30, 2020 and year to date from April 01, 2020 to September 30, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") read with SEBI Circular No. CIR/CFD/CMDI /44/2019 dated March 29, 2019 ('the Circular').

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors in their meeting held on November 10, 2020, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133, of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this Financial Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Harjeet Parvesh & Company
Chartered Accountants
FRN: Q17437N

CA Harjeet Singh
FCA
M.No 095466

Place: Mohali

Date: 10th Day of November, 2020

UDIN: 20095466AAAAGJS116.

AJOONI BIOTECH LIMITED
Unaudited Standalone Cash flow statement

(Amount Rs. In Lakhs)


	Particulars	For the half year ended	For the half year ended
		30th Sept 2020	30th Sept 2019
A. Cash flow from operating activities			
Profit/(Loss) before tax		52.45	10.90
Adjustments for:			
Depreciation and amortisation		21.30	31.63
Other Adjustment			(11.55)
Operating profit before working capital changes		73.75	30.98
Adjustments for movement in:			
Trade payables		60.71	77.73
Provisions and other liabilities		31.85	19.60
Trade receivables		2.28	(322.19)
Loans and advances and other assets		(88.94)	(23.05)
Inventories		(20.69)	0.89
Cash generated from/(used in) operations		58.96	(216.04)
Income taxes paid (including taxes deducted at source)		(13.59)	
Net cash generated from/(used in) operating activities		45.37	(216.04)
B Cash flow from investing activities :			
Purchase of fixed assets		(58.60)	(18.05)
Movement in Investments		11.71	19.39
Movement in Long term Advances		(36.02)	-
Net cash (used in) investing activities		(82.91)	1.34
C Cash flow from financing activities			
Movement in long-term borrowings		91.86	14.42
Movement in short-term borrowings		(45.77)	157.06
Net cash (used in)/generated from financing activities		46.09	171.48
Net increase in cash and cash equivalents (A+B+C)		8.54	(43.22)
Cash and cash equivalents as at 1st April		12.39	73.07
Cash and cash equivalents as at 30th September		20.92	29.85

Notes:

- a) The above cash flow statement has been prepared under the "Indirect Method" as set out in Accounting Standard 3 (AS-3) on "Cash flow statements" as specified under section 133 of Companies Act, 2013 read with Rule 7 of the
- b) Negative figures have been shown in brackets.

This is the cash flow statement referred to in our report of even date.

FOR & ON BEHALF OF THE BOARD
AJOONI BIOTECH LTD.


Jasjot Singh
Managing Director

Place : Mohali
Date : 10/11/2020



National Stock Exchange Of India Limited

Date of Download : 10-Nov-2020

NSE Acknowledgement

Symbol:-	AJOONI
Name of the Company: -	Ajooni Biotech Limited
Submission Type:-	Announcements
Short Description:-	Financial Results Updates
Date of Submission:-	10-Nov-2020 04:46:41 PM
NEAPS App. No:-	2020/Nov/4057/4066

Disclaimer : We hereby acknowledge receipt of your submission through NEAPS. Please note that the content and information provided is pending to be verified by NSEIL.